Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Malignant Lymphoma

Free Subscription Articles published in Am J Hematol Retrieve available abstracts of 67 articles: HTML format

Single Articles

September 2025
1. LIU Y, Ren Y, Gao L, Ahmed S, et al
   Endothelial Activation and Stress Index Serves as a Predictor for Survival in Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: A Retrospective Multicenter Cohort Study of Jiangsu Cooperative Lymphoma Group.
   Am J Hematol. 2025 Sep 8. doi: 10.1002/ajh.70063.
   PubMed     Abstract available
   
   
   
2. ATALLAH-YUNES SA, Nze CC, King RL, Rees MJ, et al
   Multi-Institutional Study of ALK-Positive Large B-Cell Lymphoma: Outcomes in the Era of ALK Inhibitors and Biologically Informed Therapies.
   Am J Hematol. 2025 Sep 3. doi: 10.1002/ajh.70058.
   PubMed     Abstract available
   
   
   
3. HRISTOV AC, Tejasvi T, Wilcox RA
   Mycosis Fungoides, Sezary Syndrome, and Cutaneous B-Cell Lymphomas: 2025 Update on Diagnosis, Risk-Stratification, and Management.
   Am J Hematol. 2025;100:1603-1628.
   PubMed     Abstract available
   
   
   August 2025
4. OTHMAN T, Baird JH, Wang Y, Pak S, et al
   Outpatient Brexucabtagene Autoleucel in B-Cell Acute Lymphoblastic Leukemia and Mantle Cell Lymphoma.
   Am J Hematol. 2025 Aug 20. doi: 10.1002/ajh.70038.
   PubMed    
   
   
   
5. GAUTHIER J, Ahn KW, Patel J, Lian Q, et al
   CD19 CAR T-Cell Therapy for Primary Mediastinal Large B-Cell Lymphoma: A CIBMTR Analysis.
   Am J Hematol. 2025 Aug 11. doi: 10.1002/ajh.70033.
   PubMed     Abstract available
   
   
   
6. THIRUVENGADAM SK, Ahn KW, Patel J, Lian Q, et al
   CD19 Directed CAR T Therapy for Transformed Follicular Lymphoma: A CIBMTR Analysis.
   Am J Hematol. 2025 Aug 5. doi: 10.1002/ajh.70027.
   PubMed     Abstract available
   
   
   
7. SHIMONY S, Luskin MR, Gangat N, LeBoeuf NR, et al
   Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): 2025 Update on Diagnosis, Pathophysiology, Risk Assessment, and Management.
   Am J Hematol. 2025;100:1408-1422.
   PubMed     Abstract available
   
   
   July 2025
8. CHIRIAC R, Baseggio L
   Pseudo-Chediak-Higashi Inclusions in an Anaplastic Large Cell Lymphoma.
   Am J Hematol. 2025 Jul 24. doi: 10.1002/ajh.70016.
   PubMed    
   
   
   
9. LOSSOS IS, Jiang X, Patel K, Moalem KN, et al
   Association Between Moraxella catarrhalis and Nodular Lymphocyte-Predominant Hodgkin Lymphoma.
   Am J Hematol. 2025 Jul 4. doi: 10.1002/ajh.27762.
   PubMed     Abstract available
   
   
   
10. DURMO R, Chauvie S, Minoia C, Bergesio F, et al
    Total Metabolic Tumor Volume Is a Strong Independent Prognostic Factor in Follicular Lymphomas: Results From a Sub-Study of the FOLL12 Trial.
    Am J Hematol. 2025;100:1196-1204.
    PubMed     Abstract available
    
    
    June 2025
11. BOUSKA A, Zhang W, Sharma S, Holte H, et al
    Integrative Genomic and Transcriptomic Analysis Reveals Targetable Vulnerabilities in Angioimmunoblastic T-Cell Lymphoma.
    Am J Hematol. 2025 Jun 13. doi: 10.1002/ajh.27736.
    PubMed     Abstract available
    
    
    
12. CARTER J, von Reusner JM, Sellmyer MA, Bagg A, et al
    Common Lymphoma in an Uncommon Location.
    Am J Hematol. 2025 Jun 9. doi: 10.1002/ajh.27740.
    PubMed    
    
    
    May 2025
13. WANG WJ, Lin P, Stewart JM, Tang G, et al
    ALK+ Large B-Cell Lymphoma With Novel ZNF296::ALK: A Morphologic Mimic of ALK+ Anaplastic Large Cell Lymphoma.
    Am J Hematol. 2025 May 27. doi: 10.1002/ajh.27727.
    PubMed    
    
    
    
14. ALDERUCCIO JP, Kuker RA, Edelman Saul E, Stanchina MD, et al
    PET/CT in the Staging and Treatment Response Assessment of Patients With Extranodal Marginal Zone Lymphoma.
    Am J Hematol. 2025 May 21. doi: 10.1002/ajh.27712.
    PubMed     Abstract available
    
    
    
15. STANCHINA MD, Sacher C, Melendez Y, Dudkiewicz P, et al
    Routine Screening of Strongyloides Among Patients With Lymphoma and Efficacy of Targeted Prophylaxis.
    Am J Hematol. 2025 May 19. doi: 10.1002/ajh.27719.
    PubMed     Abstract available
    
    
    April 2025
16. LUPU P, Banker L, Hammer RD
    Rocky Mountain Spotted Fever, a Lymphoma Mimic on Peripheral Blood Smear.
    Am J Hematol. 2025 Apr 28. doi: 10.1002/ajh.27695.
    PubMed    
    
    
    
17. FURQAN F, Ahn KW, Kaur M, Patel J, et al
    Autologous Transplant or CAR-T as Consolidation Options in MYC Rearranged Large B-Cell Lymphoma Patients in Remission After Salvage Treatments.
    Am J Hematol. 2025 Apr 15. doi: 10.1002/ajh.27687.
    PubMed     Abstract available
    
    
    
18. 
    Correction to "Benefit of Axicabtagene Ciloleucel Versus Chemoimmunotherapy in Older Patients and/or Patients With Poor ECOG Performance Status With Relapsed or Refractory Large B-Cell Lymphoma After 2 or More Lines of Prior Therapy".
    Am J Hematol. 2025 Apr 4. doi: 10.1002/ajh.27674.
    PubMed    
    
    
    March 2025
19. LAZARIAN G, Chemali L, Bensalah M, Zindel C, et al
    TP53 Mutations Detected by NGS Are a Major Clinical Risk Factor for Stratifying Mantle Cell Lymphoma.
    Am J Hematol. 2025 Mar 6. doi: 10.1002/ajh.27650.
    PubMed    
    
    
    February 2025
20. ROEKER LE, Han Y, Teschemaker A, Mato AR, et al
    BTK Inhibitors Versus Venetoclax as First- or Second-Line Therapy in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Real-World Evidence Study.
    Am J Hematol. 2025 Feb 17. doi: 10.1002/ajh.27639.
    PubMed    
    
    
    
21. YAMSHON S, Koff JL, Larson MC, Kahl BS, et al
    Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated With R-GemOx: A Multicenter Cohort Study.
    Am J Hematol. 2025 Feb 7. doi: 10.1002/ajh.27630.
    PubMed     Abstract available
    
    
    
22. CHEN LT, Yeh KH, Lin CW, Wang TE, et al
    Multicenter Prospective First-Line Helicobacter Pylori Eradication for Localized Gastric "Pure" Diffuse Large B-Cell Lymphoma.
    Am J Hematol. 2025 Feb 6. doi: 10.1002/ajh.27624.
    PubMed    
    
    
    January 2025
23. BRYNOLF A, Sandstrom A, Hjalgrim H, Edgren G, et al
    Association Between Red-Cell Transfusion in Childbirth and Long-Term Risk of Lymphoma and Autoimmune Disease: A Swedish Nationwide Cohort Study.
    Am J Hematol. 2025 Jan 27. doi: 10.1002/ajh.27610.
    PubMed    
    
    
    
24. KYVSGAARD ER, Grauslund M, Sjo L, Melchior LC, et al
    NOTCH1 Mutations Are Associated With Therapy-Resistance in Patients With B-Cell Lymphoma Treated With CD20xCD3 Bispecific Antibodies.
    Am J Hematol. 2025 Jan 25. doi: 10.1002/ajh.27601.
    PubMed    
    
    
    
25. ZHOU H, Huang Z, Fang B, Jing H, et al
    CM313 Monotherapy in Patients With Relapsed/Refractory Multiple Myeloma or Marginal Zone Lymphoma: A Multicenter, Phase 1 Dose-Escalation and Dose-Expansion Trial.
    Am J Hematol. 2025 Jan 22. doi: 10.1002/ajh.27573.
    PubMed    
    
    
    
26. LURAIN K, Ramaswami R, Oksenhendler E, Boutboul D, et al
    Primary Effusion Lymphoma Prognostic Score (PEL-PS): A Validated International Prognostic Score in HIV-Associated Primary Effusion Lymphoma.
    Am J Hematol. 2025 Jan 15. doi: 10.1002/ajh.27580.
    PubMed     Abstract available
    
    
    
27. SCARAMELLINI N, Canzi M, Cassinerio E, Migone De Amicis M, et al
    A Case of Hodgkin Lymphoma in a Gaucher Disease Patient: Distinguishing Gaucher and Pseudo-Gaucher Cells.
    Am J Hematol. 2025 Jan 13. doi: 10.1002/ajh.27587.
    PubMed    
    
    
    
28. LASSEN T, Nielsen TH, von Heymann A, Nielsen LK, et al
    Limited Benefit of Routine Clinical Follow-Up for Relapse Detection in Diffuse Large B-Cell Lymphoma Patients in Complete Remission Following First-Line Treatment.
    Am J Hematol. 2025 Jan 5. doi: 10.1002/ajh.27577.
    PubMed     Abstract available
    
    
    December 2024
29. THIRUVENGADAM SK, Merryman R, Wang Y, Gaulin C, et al
    Outcomes of CD19 CAR T in Transformed Indolent Lymphoma Compared to De Novo Aggressive Large B-Cell Lymphoma.
    Am J Hematol. 2024 Dec 23. doi: 10.1002/ajh.27548.
    PubMed     Abstract available
    
    
    
30. 
    Correction to "Benefit of Axicabtagene Ciloleucel Versus Chemoimmunotherapy in Older Patients and/or Patients With Poor ECOG Performance Status With Relapsed or Refractory Large B-Cell Lymphoma After 2 or More Lines of Prior Therapy".
    Am J Hematol. 2024 Dec 12. doi: 10.1002/ajh.27551.
    PubMed    
    
    
    November 2024
31. WITZIG TE, Taylor WR, Mahoney DW, Bamlet WR, et al
    Blood Plasma Methylated DNA Markers in the Detection of Lymphoma: Discovery, Validation, and Clinical Pilot.
    Am J Hematol. 2024 Nov 20. doi: 10.1002/ajh.27533.
    PubMed     Abstract available
    
    
    
32. LONE W, Bouska A, Herek TA, Amador C, et al
    High-grade B-cell lymphoma not otherwise specified, with diffuse large B-cell lymphoma gene expression signatures: Genomic analysis and potential therapeutics.
    Am J Hematol. 2024 Nov 16. doi: 10.1002/ajh.27513.
    PubMed     Abstract available
    
    
    
33. LUO J, Zhang J, Liu L, Wei R, et al
    Efficacy and safety of zanubrutinib monotherapy for chronic lymphocytic leukemia/small lymphocytic lymphoma: A multicenter, real-world study in China.
    Am J Hematol. 2024 Nov 4. doi: 10.1002/ajh.27519.
    PubMed    
    
    
    October 2024
34. ATALLAH-YUNES SA, Rees MJ, Mwangi R, Kuchler RL, et al
    Characteristics and outcomes of incidentally diagnosed diffuse large B-cell lymphoma and implications for cancer screening.
    Am J Hematol. 2024 Oct 14. doi: 10.1002/ajh.27504.
    PubMed     Abstract available
    
    
    
35. LI P, Liu W, Zhou L, Ye S, et al
    C-CAR066, a novel fully human anti-CD20 CAR-T therapy for relapsed or refractory large B-cell lymphoma after failure of anti-CD19 CAR-T therapy: A phase I clinical study.
    Am J Hematol. 2024 Oct 1. doi: 10.1002/ajh.27488.
    PubMed     Abstract available
    
    
    
36. 
    Abstracts from the 2024 Lymphoma Leukemia and Myeloma Congress October 16-19, 2024.
    Am J Hematol. 2024;99 Suppl 2:S3-S64.
    PubMed    
    
    
    September 2024
37. ANSELL SM
    Hodgkin lymphoma: 2025 update on diagnosis, risk-stratification, and management.
    Am J Hematol. 2024 Sep 6. doi: 10.1002/ajh.27470.
    PubMed     Abstract available
    
    
    August 2024
38. GUNAWARDANA J, Law SC, Sabdia MB, Fennell E, et al
    Intra-tumoral and peripheral blood TIGIT and PD-1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphoma.
    Am J Hematol. 2024 Aug 17. doi: 10.1002/ajh.27459.
    PubMed     Abstract available
    
    
    
39. VEILLEUX O, Socola F, Arai S, Frank MJ, et al
    Management of post-autologous transplant relapse in patients with T-cell lymphomas.
    Am J Hematol. 2024;99:1485-1491.
    PubMed     Abstract available
    
    
    July 2024
40. MALPICA L, Marques-Piubelli ML, Beltran BE, Chavez JC, et al
    EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2024 update on the diagnosis, risk-stratification, and management.
    Am J Hematol. 2024 Jul 3. doi: 10.1002/ajh.27430.
    PubMed     Abstract available
    
    
    June 2024
41. ABABNEH HS, Ng AK, Frigault MJ, Jacobson CA, et al
    Radiotherapy as a bridging strategy for patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy.
    Am J Hematol. 2024 Jun 11. doi: 10.1002/ajh.27409.
    PubMed    
    
    
    
42. TUN AM, Patel RD, St-Pierre F, Ouchveridze E, et al
    Anti-CD19 chimeric antigen receptor T-cell therapy in older patients with relapsed or refractory large B-cell lymphoma: A multicenter study.
    Am J Hematol. 2024 Jun 4. doi: 10.1002/ajh.27381.
    PubMed     Abstract available
    
    
    
43. MANJERI A, Lee SY, Ng SB, Lee CT, et al
    Plasmablastic lymphoma in the pleural cavity.
    Am J Hematol. 2024 Jun 1. doi: 10.1002/ajh.27387.
    PubMed    
    
    
    May 2024
44. ALSOUQI A, Ahmed G, Wang J, Cassanello G, et al
    Chimeric antigen receptor T-cell therapy in secondary central nervous system lymphoma: A multicenter analysis.
    Am J Hematol. 2024 May 20. doi: 10.1002/ajh.27354.
    PubMed    
    
    
    
45. RAMIREZ-GAMERO A, Martinez-Cordero H, Beltran BE, Florindez J, et al
    Plasmablastic lymphoma: 2024 update on diagnosis, risk stratification, and management.
    Am J Hematol. 2024 May 20. doi: 10.1002/ajh.27376.
    PubMed     Abstract available
    
    
    
46. 
    Correction to "Benefit of axicabtagene ciloleucel vs chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapy".
    Am J Hematol. 2024 May 7. doi: 10.1002/ajh.27356.
    PubMed    
    
    
    
47. YUEN S, Phillips TJ, Bannerji R, Marlton P, et al
    Polatuzumab vedotin, venetoclax, and an anti-CD20 monoclonal antibody in relapsed/refractory B-cell non-Hodgkin lymphoma.
    Am J Hematol. 2024 May 3. doi: 10.1002/ajh.27341.
    PubMed     Abstract available
    
    
    
48. MOU E, Fernandez-Pol S, Li S, Rieger KE, et al
    Clinical characteristics, treatment patterns, and outcomes of cytotoxic cutaneous T-cell lymphomas.
    Am J Hematol. 2024;99:985-988.
    PubMed    
    
    
    April 2024
49. MA S, La J, Swinnerton KN, Guffey D, et al
    Thrombosis risk prediction in lymphoma patients: A multi-institutional, retrospective model development and validation study.
    Am J Hematol. 2024 Apr 23. doi: 10.1002/ajh.27335.
    PubMed     Abstract available
    
    
    
50. CHOQUET S, Soussain C, Azar N, Morel V, et al
    CAR T-cell therapy induces a high rate of prolonged remission in relapsed primary CNS lymphoma: Real-life results of the LOC network.
    Am J Hematol. 2024 Apr 8. doi: 10.1002/ajh.27316.
    PubMed     Abstract available
    
    
    March 2024
51. STUVER R, Mian A, Brown S, Devlin S, et al
    BEAM versus pharmacokinetics-directed BuCyVP16 conditioning for patients with peripheral T-cell lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation.
    Am J Hematol. 2024 Mar 25. doi: 10.1002/ajh.27291.
    PubMed    
    
    
    
52. LUNNING MA, Wang HL, Hu ZH, Locke FL, et al
    Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapy.
    Am J Hematol. 2024 Mar 19. doi: 10.1002/ajh.27283.
    PubMed     Abstract available
    
    
    
53. ONG SY, Zain JM
    Aggressive T-cell lymphomas: 2024: Updates on diagnosis, risk stratification, and management.
    Am J Hematol. 2024;99:439-456.
    PubMed     Abstract available
    
    
    February 2024
54. KITTAI AS, Hang Y, Bhat SA, Clark A, et al
    Racial disparities in chronic lymphocytic leukemia/small lymphocytic lymphoma accounting for small molecule inhibitors: A real-world cohort analysis.
    Am J Hematol. 2024 Feb 15. doi: 10.1002/ajh.27241.
    PubMed     Abstract available
    
    
    
55. JABBOUR E, Zugmaier G, Agrawal V, Martinez-Sanchez P, et al
    Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia.
    Am J Hematol. 2024 Feb 5. doi: 10.1002/ajh.27227.
    PubMed     Abstract available
    
    
    
56. WILSON MR, Kirkwood AA, Wong Doo N, Soussain C, et al
    Dosage of high-dose methotrexate as CNS prophylaxis in DLBCL: A detailed analysis of toxicity and impact on CNS relapse.
    Am J Hematol. 2024;99:E46-E50.
    PubMed    
    
    
    January 2024
57. 
    Correction to "Analysis of 60 Patients with Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia and T-cell Lymphoblastic Lymphoma Treated with CD7-targeted Chimeric Antigen Receptor-T Cell Therapy".
    Am J Hematol. 2024 Jan 15. doi: 10.1002/ajh.27217.
    PubMed    
    
    
    
58. CERHAN JR, Maurer MJ, Link BK, Feldman AL, et al
    The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes.
    Am J Hematol. 2024 Jan 13. doi: 10.1002/ajh.27202.
    PubMed     Abstract available
    
    
    
59. QIAN H, Yang X, Zhang T, Zou P, et al
    Improving the safety of CAR-T-cell therapy: The risk and prevention of viral infection for patients with relapsed or refractory B-cell lymphoma undergoing CAR-T-cell therapy.
    Am J Hematol. 2024 Jan 10. doi: 10.1002/ajh.27198.
    PubMed     Abstract available
    
    
    November 2023
60. AL-SARAYFI D, Brink M, Chamuleau MED, Brouwer R, et al
    R-miniCHOP versus R-CHOP in elderly patients with diffuse large B-cell lymphoma: A propensity matched population-based study.
    Am J Hematol. 2023 Nov 28. doi: 10.1002/ajh.27151.
    PubMed     Abstract available
    
    
    
61. HONG HG, Gouveia MH, Ogwang MD, Kerchan P, et al
    Sickle cell allele HBB-rs334(T) is associated with decreased risk of childhood Burkitt lymphoma in East Africa.
    Am J Hematol. 2023 Nov 27. doi: 10.1002/ajh.27149.
    PubMed     Abstract available
    
    
    
62. SAIFI O, Lester SC, Breen WG, Rule WG, et al
    Incorporating radiation with anti-CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory non-Hodgkin lymphoma: A multicenter consensus approach.
    Am J Hematol. 2023 Nov 11. doi: 10.1002/ajh.27155.
    PubMed     Abstract available
    
    
    
63. REJESKI K, Wang Y, Albanyan O, Munoz J, et al
    The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL.
    Am J Hematol. 2023;98:1699-1710.
    PubMed     Abstract available
    
    
    October 2023
64. 
    Abstracts from the 2023 Lymphoma, Leukemia and Myeloma Congress October 18-21, 2023.
    Am J Hematol. 2023;98 Suppl 5:S3-S57.
    PubMed    
    
    
    September 2023
65. ZHANG X, Yang J, Li J, Qiu L, et al
    Analysis of 60 patients with relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma treated with CD7-targeted chimeric antigen receptor-T cell therapy.
    Am J Hematol. 2023 Sep 23. doi: 10.1002/ajh.27094.
    PubMed     Abstract available
    
    
    
66. 
    Erratum to: Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma.
    Am J Hematol. 2023 Sep 21. doi: 10.1002/ajh.27103.
    PubMed    
    
    
    
67. ONG SY, Pak S, Mei M, Wang Y, et al
    Bendamustine lymphodepletion is a well-tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B-cell lymphoma.
    Am J Hematol. 2023 Sep 5. doi: 10.1002/ajh.27069.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge.